drugset
drugset / Trial / NCT05104788

A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer

NCT05104788 ↗

Phase 2 Recruiting 27 enrolled Peking University Cancer Hospital & Institute
NaSingle-groupOpen-labelTreatment

Summary

This is a Phase II, single-Arm, prospective study of neoadjuvant Icotinib with chemotherapy for the treatment of patients with epidermal growth factor receptor mutation positive, resectable for stage II to IIIB(N2) Non-small Cell Lung Cancer

Timeline

Start
2021-10-25
Primary completion
2024-03-01
Completion
2026-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Icotinib Small molecule 125 mg Oral
Background Carboplatin Small molecule — —
Background Cisplatin Other / unclassified 75 mg/m2 —
Background Pemetrexed Small molecule 500 mg/m2 —

Indications

non-small cell lung carcinoma